Business Context and Reporting Period
Company: Boston Scientific Corporation
Filing Type: Form 8-K (Current Report)
Date of Report: February 26, 2026
Primary Event: Entry into new material definitive credit agreements to support liquidity and the proposed acquisition of Penumbra, Inc.
Key Financial Metrics and Debt Structure
This filing details the establishment of a new credit facility structure ("2026 Credit Agreements") rather than reporting operational financial results (revenue, profit, or cash flow). Key debt metrics include:
- 2026 Revolving Credit Agreement: $3.0 billion capacity; matures February 26, 2031 (with one-year extension options).
- 364-Day Revolving Credit Agreement: $2.0 billion capacity; matures 364 days from the earlier of availability or the Penumbra acquisition closing.
- Term Loan Credit Agreement: $6.0 billion total capacity structured as delayed draw term loans:
- Tranche A: Up to $1.0 billion.
- Tranche B: Up to $5.0 billion (subject to reduction by equity/debt proceeds).
- Interest Rates: Based on Term SOFR, Alternate Base Rate (ABR), or Eurocurrency Rate plus applicable margins tied to the Company's Credit Rating.
- Financial Covenants: Maximum Leverage Ratio capped at 3.75x. This increases to 4.75x for four quarters following a "Qualified Acquisition" (exceeding $1.0 billion in debt), then steps down to 3.75x over the subsequent three quarters.
Material Changes Versus Prior Period
- Termination of Prior Facility: The Company terminated its previous revolving credit agreement (dated May 10, 2021, as amended) effective February 26, 2026.
- Acquisition Financing: The new Term Loan Credit Agreement is specifically structured to fund the acquisition of Penumbra, Inc., with drawdowns contingent on the closing of that transaction.
- Liquidity Strategy: The Company has shifted from a single revolving facility to a multi-facility structure including long-term revolving credit, short-term revolving credit, and delayed draw term loans.
Guidance, Outlook, and Risks
Management Commentary and Outlook: The filing indicates the Company is actively preparing for the Penumbra acquisition, securing up to $11.0 billion in total committed credit facilities ($3.0B + $2.0B + $6.0B) to ensure funding availability.
Risks and Contingencies:
- Acquisition Dependency: The $6.0 billion Term Loan and the maturity of the $2.0 billion 364-Day Revolver are contingent on the closing of the Penumbra acquisition.
- Refinancing Requirement: Tranche B loans ($5.0 billion) must be repaid or refinanced with proceeds from subsequent equity issuance or debt incurrence if drawn.
- Covenant Compliance: The Company must maintain a Maximum Leverage Ratio of 3.75x (or 4.75x post-acquisition). Failure to meet covenants could result in termination of commitments and acceleration of loans.
- EBITDA Adjustments: The agreement permits exclusions from Consolidated EBITDA for non-cash charges and cash litigation payments (up to $1.16 billion aggregate since Dec 31, 2025).
Important Facts for Investor Verification
- Verify the status and expected closing date of the Penumbra, Inc. acquisition, as it triggers the drawdown of $6.0 billion in term loans.
- Confirm the Company's current Credit Rating, as interest margins and facility fees are directly tied to this rating.
- Monitor the Company's leverage ratio to ensure compliance with the 3.75x (or 4.75x post-acquisition) covenant.
- Review the 2025 Form 10-K (filed Feb 17, 2026) for details on the terminated 2021 Revolving Credit Agreement and historical debt levels.
- Assess the Company's ability to refinance the $5.0 billion Tranche B loans via equity or debt issuance if the term loans are drawn.